This article is more than 5 years old. Information may no longer be current.

Aerie Pharmaceuticals reports third quarter loss of $23.8 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals reported a net loss of $23.8 million, or $0.81 per share, in the third quarter, compared with a net loss of $18 million, or $0.69 per share, in the third quarter of 2015.

A company press release attributed $23.3 million of the loss to operating expenses: $12.7 million in research and development expenses and $10.6 million in general and administrative expenses.

The higher operating expenses in the third quarter compared with a year ago were due to an expansion of the company’s employee base and clinical activities related to phase 3 programs for its product candidates, the release said.